Today, (8 July 2010), Cyprotex announces that it has extended its Cloe® Screen Cytochrome P450 Isoform Identification (Reaction Phenotyping) service to include an additional cytochrome P450 isoform, CYP2B6. The assay uses isoform-specific recombinant enzyme to investigate whether a particular cytochrome P450 isoform is involved in the metabolism of a potential new drug.
Cytochrome P450 enzymes are a family of enzymes which play a major role in the metabolism of drugs. Identifying the particular cytochrome P450 responsible for metabolism of a drug is important for several reasons. Firstly, the information may be used to predict potential drug-drug interactions with co-administered compounds which are metabolised by the same enzyme. Secondly, certain cytochrome P450 enzymes are polymorphic (e.g. CYP2D6) and metabolism can vary considerably between individuals. If a compound is metabolised by an isoform which exhibits these characteristics, it may be detrimental, as plasma concentrations can vary considerably between subjects and determining an effective therapeutic range may be difficult.
The importance of CYP2B6 in clinical interactions has been highlighted in a US FDA update paper by Huang et al., 2008 (J Clin Pharmacol 48; 662-670). This update advises that CYP2B6 should be included in the panel of cytochrome P450 isoforms assessed during in vitro interaction studies.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the launch of the extended service. ‘By expanding our existing service offering to our clients, we are responding to regulatory guidelines as well as customer demand. Understanding cytochrome P450 interactions is an importance issue which can be screened for at an early stage of drug discovery using a battery of well-established reliable tests.’
For further information:
Helen Gill PhD, Product Development Manager
Tel: +44 (0)1625 505 100